科学无止境，探索永不停。新型冠状病毒肺炎疫情常态化的当下，学术的进步与传递仍未停止。万众期待之下，美国临床肿瘤学会泌尿生殖系统肿瘤研讨会（ASCO-GU）将于2022年2月17~19日以线上结合线下的形式召开。本次会议公布了多项泌尿肿瘤领域的研究结果，其中前列腺癌的精准诊断、智能优化管理与靶向治疗是本次大会的热点之一，因此本文就ASCO-GU 2022会议中的重磅研究大会口头报告，让我们先看看今年入选重磅研究有哪些吧！具体研究详情，请关注【肿瘤资讯】后续报道。
2月17日
新型治疗实施：前列腺特异性膜抗原靶向及其他
PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)
PSMA PET和 FDG PET在177Lu-PSMA-617（LuPSMA）对比卡巴他赛治疗经多西他赛进展的转移行去势抵抗性前列腺癌（mCRPC）的随机2期试验中作为疗效反应和预后判断的预测因子
演讲者：James Patrick Buteau
摘要号：10
2月18日
优化局部前列腺癌的管理：人工智能、主动监测和干预
1.Development and validation of a prognostic AI biomarker using multi-modal deep learning with digital histopathology in localized prostate cancer on NRG Oncology phase III clinical trials.
在NRG Oncology III期临床试验中使用多模式深度学习和数字组织病理学作为局限性前列腺癌的预后性人工智能生物标志物的开发和验证。
演讲者：Andre Esteva
摘要号：222
2.NRG/RTOG 9408研究：人工智能衍生的基于数字病理学的生物标记物用于预测局限性前列腺癌雄激素剥夺治疗的获益
An AI-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy in localized prostate cancer with validation in NRG/RTOG 9408.
演讲者：Daniel Eidelberg Spratt
摘要号：223
口头报告：前列腺癌
1.PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
PROpel III 期试验：奥拉帕尼和阿比特龙联合用药作为转移性去势抵抗性前列腺癌 (mCRPC) 患者的一线治疗的安全性和有效性
演讲者：Fred Saad
摘要号：11
2.Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.
MAGNITUDE III 期试验：尼拉帕尼 (NIRA) 与醋酸阿比特龙和泼尼松 (AAP) 作为一线治疗具有和不具有同源重组修复 (HRR) 基因的转移性去势抵抗性前列腺癌 (mCRPC) 患者 (pts) 的结果更新
演讲者：Kim N. Chi
摘要号：12
3.Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.
ARASENS III 期试验：darolutamide 与安慰剂联合雄激素剥夺疗法和多西他赛治疗转移性激素敏感性前列腺癌的总生存期大揭晓
演讲者：Matthew Raymond Smith
摘要号：13
4.A randomized, double-blind, placebo (PBO)-controlled, phase 3b study of the efficacy and safety of continuing enzalutamide (ENZA) in chemotherapy-naïve, metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (DOC) plus prednisolone (PDN) who have progressed on ENZA: PRESIDE.
PRESIDE随机、双盲、安慰剂对照的 3b 期研究：持续使用恩杂鲁胺 (ENZA) +泼尼松龙 (PDN)+多西他赛治疗的未接受过化疗的转移性去势抵抗性前列腺癌 (mCRPC) 患者的安全性和疗效
演讲者：Axel S. Merseburger
摘要号：15
跨前列腺癌谱的多学科管理的演变
1.Detection Rate of 18F-rhPSMA-7.3 PET in Patients with Suspected Prostate Cancer Recurrence: Results from a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)
SPOTLIGHT多中心 III 期试验：前列腺癌疑似复发患者中18F-rhPSMA-7.3 PET的检出率
演讲者：David M. Schuster
摘要号：9
快速口头摘要. 前列腺癌
1.Randomized phase II trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP.
ACDC-RP随机II期试验: 新辅助阿比特龙联合或不联合卡巴他赛治疗高危前列腺癌的安全性和疗效
演讲者：Neil E. Fleshner
摘要号：224
2.Identifying patient profiles and mapping the patient journey across three countries in a large-scale, fully digital survey of patients with prostate cancer.
大规模、全数字调查：三个国家中前列腺癌患者患者特征和分布
演讲者：Alicia K. Morgans
摘要号：16
3.Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).
ARV-110的Ⅰ/Ⅱ期研究：一种雄激素受体[AR]PROTAC降解剂治疗转移性去势抵抗性前列腺癌(mCRPC)
演讲者：Xin Gao
摘要号：17
4.Bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone plus prednisone in the PEACE-1 phase 3 trial.
PEACE-1 III 期试验：接受或未接受阿比特龙加泼尼松治疗的新发转移性去势敏感性前列腺癌男性患者的骨密度揭晓。
演讲者：Guilhem Roubaud
摘要号：18
5.Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES).
ODM-208首次人体Ⅰ/Ⅱ试验，在转移性去势抵抗性前列腺癌(CYPIDES)患者治疗Ⅰ期结果揭晓：
演讲者：Karim Fizazi
摘要号：19
1.Primary analysis from DS8201-A-U105: A phase 1b, 2-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).
DS8201-A-U105:deruxtecan(T-DXd)联合纳武利尤单抗治疗HER2表达的尿路上皮癌(UC)患者安全性和有效性。
演讲者：Matt D. Galsky,
摘要号：438
2.First line avelumab in PD-L1+ve metastatic or locally advanced urothelial cancer (aUC) patients unfit for cisplatin (cis): The ARIES trial.
ARIES试验：avelumab治一线疗不适合顺铂(cis)的PD-L1 + ve转移性或局部晚期尿路上皮癌(aUC)患者疗效
演讲者：Roberto Iacovell
摘要号：439
3.Final results of a multicenter prospective phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma.
多中心前瞻性II期临床试验的最终结果：吉西他滨和顺铂作为高级别上尿路尿路上皮癌患者新辅助化疗的疗效和安全性。
演讲者：Wesley Yip
摘要号：440
4.Tailored immunotherapy approach with nivolumab in advanced transitional cell carcinoma (TITAN-TCC).
TITAN-TCC：纳武利尤单抗治疗晚期移行细胞癌的定制免疫治疗方法。
演讲者：Marc-Oliver Grimm
摘要号：441
5.Randomized phase II study of niraparib plus best supportive care (BSC) versus BSC alone as maintenance treatment in patients with advanced urothelial carcinoma (UC) whose disease did not progress after first-line platinum-based chemotherapy (PBCT): The Meet-URO12 trial.
Meet-URO12随机、II期研究：比较niraparib + 最佳支持治疗(BSC)与BSC单药维持治疗：在一线含铂化疗(PBCT)后疾病未进展的晚期尿路上皮癌(UC)患者中安全性与疗效。
演讲者：Francesca Vignani
摘要号：442
2月19日
1.First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.
LEAP-011随机化、双盲III 期试验：帕博利珠单抗(pembro)联合或不联合仑伐替尼(lenva)一线治疗晚期尿路上皮癌患者的安全性和有效性
演讲者：Yohann Loriot
摘要号：432
尿路上皮癌热点话题
1.ctDNA Analysis in Muscle-Invasive Bladder Cancer: Therapy Response, Risk of Recurrence, and Early Relapse Detection
肌层浸润性膀胱癌的 ctDNA 分析：治疗反应、复发风险和早期复发检测
演讲者：Lars Dyrskjøt（PPT）
2.Multi-institutional matched comparison of radical cystectomy to trimodality therapy for muscle-invasive bladder cancer.
多机构匹配中比较肌层浸润性膀胱癌根治性膀胱切除术与三联疗法（摘要）
演讲者：Alexandre R. Zlotta
摘要号：433
3.New Evidence to Optimize Bladder Preservation
优化膀胱保护的新证据
演讲者：Shaista Hafeez（PPT）
4.Endoscopic Management of Low-Grade Upper-Tract Urothelial Carcinoma
低级别上尿路上皮癌的内镜治疗
演讲者：Surena F. Matin（PPT）
5.Race and Gender Disparities in Standard-of-Care Practice in Bladder Cancer
分子生物标志物在上尿路上皮癌中的临床意义
演讲者：Janet Baack Kukreja（PPT）
口头摘要：尿路上皮癌
1.TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.
TROPHY-U-01队列研究：戈沙妥珠单抗联合帕博利珠单抗用于基于铂类治疗进展的转移性尿路上皮癌患者疗效揭晓
演讲者：Petros Grivas
摘要号：434
2.Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible.
研究EV-103队列H：在不适合接受顺铂治疗的肌层浸润性膀胱癌(MIBC)患者中评价enfortumab vedotin单药新辅助治疗的抗肿瘤活性。
演讲者：Daniel P. Petrylak
摘要号：435
3.A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm.
ATLANTIS rucaparib随机、双盲、生物标志物选择、II期临床试验最终分析：化疗后维持PARP抑制的治疗转移性尿路上皮癌(mUC)的安全性
演讲者：Simon J. Crabb
摘要号：436
4.BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC).
BAYOU随机、多中心、双盲Ⅱ期研究：度伐利尤单抗联合奥拉帕利一线治疗的不适合铂类的、不可切除的、Ⅳ期尿路上皮癌患者的安全性和疗效
演讲者：Jonathan E. Rosenberg,
摘要号：437
揭开尿路上皮癌下一代测序的神秘面纱：一种基于病例的方法
1.Positive efficacy and safety phase 3 results in both CIS and papillary cohorts BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) after IL-15RαFc superagonist N-803 (Anktiva) and BCG infusion.
在卡介苗无反应性非肌层浸润性膀胱癌（NMIBC）的膀胱原位癌和乳头状癌队列中，应用IL-15RαFc超级激动剂N-803（Anktiva）和卡介苗灌注后表现出疗效和安全性
演讲者：Sam S. Chang
摘要号：431
2月20日
1.Comprehensive genomic profiling of penile squamous cell carcinoma and impact of HPV status on immune-checkpoint inhibition-related biomarkers.
阴茎鳞状细胞癌的全面基因组分析和HPV状态对免疫检查点抑制相关生物标志物的影响。
演讲者：Bassel Nazha
摘要号：4
2.Differentially expressed mRNA/proteins can distinguish viable germ cell tumors and teratomas from necrosis in retroperitoneal lymph node resections after chemotherapy (pcRPLND).
在化疗后腹膜后淋巴结切除(pcRPLND)中, mRNA/蛋白差异性表达可以区分存活的生殖细胞肿瘤和畸胎瘤与坏死。
演讲者：Tim Nestler
摘要号：408
3.A phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma.
纳武利尤单抗和阿昔替尼治疗晚期肾细胞癌患者的I/II期研究。
演讲者：Matthew R. Zibelman
摘要号：291
4.Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with clear cell RCC (ccRCC): Impact of FLCN genomic alteration (GA) status.
肾嫌色细胞癌(chrRCC)与透明细胞RCC(ccRCC)的综合基因组分析(CGP)：FLCN基因组改变(GA)状态对癌症的影响。
演讲者：Gennady Bratslavsky,
摘要号：292
5.Novel predictive biomarkers of response to immune checkpoint blockade with nivolumab ± ipilimumab in the TITAN-RCC phase 2 trial.
TITAN-RCC Ⅱ期试验：纳武利尤单抗±伊匹木单抗免疫检查点阻断反应的新型预测生物标志物。
演讲者：Marc-Oliver Grimm,
摘要号：367
肾细胞癌中的新兴生物标志物和疗法
1.Molecular alterations across sites of metastasis in patients with renal cell carcinoma (RCC).
肾细胞癌(RCC)患者不同转移部位的分子改变
演讲者：Rana R. McKay
摘要号：287
口头摘要：肾细胞癌和罕见肿瘤
1.Clinical results of PERICLES: A phase II trial investigating atezolizumab +/- radiotherapy for advanced squamous cell carcinoma of the penis.
PERICLESII期试验：阿替利珠单抗+/-放疗治疗晚期阴茎鳞状细胞癌的临床结果
演讲者：Hielke Martijn de Vries, M
摘要号：3
2.First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.
佐剂首次随机试验:米托坦辅助治疗肾上腺皮质癌患者的疗效
演讲者：Alfredo Berruti
摘要号：1
3.Efficacy, safety, and biomarker analysis of neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).
新辅助avelumab/阿昔替尼治疗肾切除术(NeoAvAx)后复发风险高的局部肾细胞癌(RCC)患者(pts)的疗效、安全性和生物标志物分析。
演讲者：Axel Bex
摘要号：289
4.Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.
KEYNOTE-564：帕博利珠单抗作为肾切除术后肾细胞癌患者的辅助治疗的30个月随访结果公开
演讲者：Toni K. Choueiri
摘要号：290
从基因检测到全身治疗：肾细胞癌病例小组
1.Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report.
HCRN GU16-260-队列A II期研究最终报告揭晓：纳武利尤单抗和挽救性纳武利尤单抗联合伊匹木单抗治疗晚期肾透明细胞癌初治患者的安全性和疗效
演讲者：Michael B. Atkin
摘要号：288
排版编辑：肿瘤资讯-Shire
苏公网安备32059002004080号
